Bispecific antibodies in oncology

Teclistamab Elranatamab ORR 차이 거의 없음 https://www.ajmc.com/view/phase-3-trials-in-high-risk-mds-highlight-future-directions Phase 3 Trials in High-Risk MDS Highlight Future Directions A recent review emphasizes a need for novel therapies, summarizes current phase 3 clinical trials, and suggests several considerations for future trials in high-risk myelodysplastic syndromes (MDS). www.ajmc.com https://www.pfizer.com/news/press-release/press-release-detail/pfizers-elranatamab-granted-fda-breakthrou...

원문링크 : Bispecific antibodies in oncology